Diamond Publications - Search Results

Search Again...

These results only include publications that have been reviewed and processed by Diamond Light Source. To also view papers that have not yet been processed click here.

You can use the folder icon under Actions to collate papers as required. You can then click on View Folder in the left-hand navigation to review and/or download your folder.

One item found (0 items not approved).

Instruments / Technical Area	Publication Details	Published	Actions
I02-Macromolecular Crystallography	Identification of the first structurally validated covalent ligands of the small GTPase RAB27A Mostafa Jamshidiha , Thomas Lanyon-Hogg , Charlotte L. Sutherell , Gregory B. Craven , Montse Tersa , Elena De Vita , Delia Brustur , Inmaculada Perez-Dorado , Sarah Hassan , Rita Petracca , Rhodri M. Morgan , Máximo Sanz-Hernández , Jim C. Norman , Alan Armstrong , David J. Mann , Ernesto Cota , Edward W. Tate Rsc Medicinal Chemistry 22 DOI: 10.1039/D1MD00225B Diamond Proposal Number(s): [17221, 23620] Open Access Show Abstract ▼ Abstract: Rab27A is a small GTPase, which mediates transport and docking of secretory vesicles at the plasma membrane via protein–protein interactions (PPIs) with effector proteins. Rab27A promotes the growth and invasion of multiple cancer types such as breast, lung and pancreatic, by enhancing secretion of chemokines, metalloproteases and exosomes. The significant role of Rab27A in multiple cancer types and the minor role in adults suggest that Rab27A may be a suitable target to disrupt cancer metastasis. Similar to many GTPases, the flat topology of the Rab27A-effector PPI interface and the high affinity for GTP make it a challenging target for inhibition by small molecules. Reported co-crystal structures show that several effectors of Rab27A interact with the Rab27A SF4 pocket (‘WF-binding pocket’) via a conserved tryptophan–phenylalanine (WF) dipeptide motif. To obtain structural insight into the ligandability of this pocket, a novel construct was designed fusing Rab27A to part of an effector protein (fRab27A), allowing crystallisation of Rab27A in high throughput. The paradigm of KRas covalent inhibitor development highlights the challenge presented by GTPase proteins as targets. However, taking advantage of two cysteine residues, C123 and C188, that flank the WF pocket and are unique to Rab27A and Rab27B among the >60 Rab family proteins, we used the quantitative Irreversible Tethering (qIT) assay to identify the first covalent ligands for native Rab27A. The binding modes of two hits were elucidated by co-crystallisation with fRab27A, exemplifying a platform for identifying suitable lead fragments for future development of competitive inhibitors of the Rab27A-effector interaction interface, corroborating the use of covalent libraries to tackle challenging targets.	Dec 2021

Instruments / Technical Area

Publication Details

Published

Actions

I02-Macromolecular Crystallography

Identification of the first structurally validated covalent ligands of the small GTPase RAB27A